InterMune Inc

InterMune — Technical Presentation (February 2014)

25 slides from InterMune's technical presentation, Feb 25, 2014

  1. Slide 1: ASCEND Top-Line Results

    ASCEND Top-Line Results February 25, 2014 Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that, without limitation, statements in this presentation regarding InterMune's plans and ex

  3. Slide 3: Topics of Today's Call

    Topics of Today’s Call IPF Disease Overview ASCEND Top-Line Results NDA Resubmission Timeline Questions and Answers Assessing Clinically Meaningful Changes in Forced Vital Capacity (FVC)

  4. Slide 4: Dan Welch, Chairman, CEO and President

    Dan Welch Chairman, CEO and President

  5. Slide 5: Our Franchise: Idiopathic Pulmonary Fibrosis (IPF)

    Our Franchise: Idiopathic Pulmonary Fibrosis (IPF) A Large, Lethal Orphan Disease % Patients Surviving at 5 Years Progressive scarring of the lungs with no known cause – Median survival: 2-5 years* Large market in North America + European Top-15: – 118K to 158K prevalence – 28K to 37K incidence Esbr

  6. Slide 6: IPF in the United States

    IPF in the United States U.S. IPF Prevalence Mild to Moderate (30,000-50,000) Severe (~20,000) Large Orphan Disease – Incidence ~ 15-20K/year – Prevalence ~ 30-50K mild/moderate Desperate Unmet Need – No FDA-approved IPF medicines Attractive Business Model – Value based, orphan disease pricing – Sma

  7. Slide 7: Jonathan Leff, M.D., EVP, Research and Development

    Jonathan Leff, M.D. EVP, Research and Development

  8. Slide 8: Clinically Meaningful Changes in FVC in IPF Studies (1)

    Clinically Meaningful Changes in FVC in IPF Studies (1) How to Determine a Clinically Relevant Change The Clinical Reality: – Disease heterogeneity – individuals progress at different rates – A population mean may underrepresent the true clinical impact to an individual – Therefore group MEAN declin

  9. Slide 9: Clinically Meaningful Changes in FVC in IPF Studies (2)

    Clinically Meaningful Changes in FVC in IPF Studies (2) Why is Categorical Change in FVC clinically meaningful? – Measures changes in an individual patient – Addresses the statistical challenge of the population mean – Can be easily tied to the MCID (a population mean cannot) – Relevant to clinician

  10. Slide 10: The ASCEND Study: Randomized Placebo Controlled Trial of Pirfenidone in IPF

    The ASCEND Study: A Randomized, Double-blind, Placebo Controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

  11. Slide 11: ASCEND Study Design: Overview

    ASCEND Study Design: Overview Randomized, double-blind, placebo controlled trial Eligible patients randomized (1:1) to treatment with pirfenidone 2403 mg/d or matched placebo for 52 weeks Centralized review of HRCT, SLB, spirometry and deaths instituted to confirm eligibility and ensure high-quality

  12. Slide 12: ASCEND Study Design: Pre-Specified Efficacy Endpoints

    ASCEND Study Design: Pre-Specified Efficacy Endpoints Primary Endpoint: %FVC Change from Baseline to Week 52 – Primary analysis: Rank ANCOVA model – Magnitude of effect: categorical analysis of 2 clinically important thresholds of change ( 10% decline or death, no decline) Key Secondary Endpoints* –

  13. Slide 13: ASCEND Study: Key Eligibility Criteria

    ASCEND Study: Key Eligibility Criteria Age 40–80 years Confident diagnosis of IPF based on central review of HRCT +/- SLB Percent predicted FVC 50% and 90% Percent predicted DLco 30% and 90% FEV /FVC ratio 0.80 6MWD 150 m

  14. Slide 14: Primary Efficacy Analysis: %FVC Change at Week 52

    Primary Efficacy Analysis: %FVC Change at Week 52 Relative Difference 54.0%** 58.0%** 57.8%** 47.9%* Pirfenidone (N=278) Placebo (N=277) p<0.000001* Proportion of Patients with %FVC Decline 10% or Death *Rank ANCOVA (pirfenidone vs. placebo) **Rank ANCOVA p<0.0001 Week

  15. Slide 15: Primary Efficacy Analysis: %FVC Change at Week 52

    Primary Efficacy Analysis: %FVC Change at Week 52 *Rank ANCOVA (pirfenidone vs. placebo at week 52) 47.9% Reduction 132.5% Increase Proportion of Patients with Clinically Important Thresholds of %FVC Change p<0.000001* 10% Decline or Death No Decline (Change >0%) Pirfenidone (N=278) Placebo (N=277)

  16. Slide 16: Key Secondary Endpoints: 6MWD and PFS

    Key Secondary Endpoints*: 6MWD and PFS Relative Reduction P-value (Rank ANCOVA) 6MWD Results 27.5% 0.0360 Proportion of Patients with 6MWD Decline meters or Death Hazard Ratio (95% CI) P-value (Log Rank) PFS Results 0.57 (0.43-0.77) 0.0001 Progression-Free Survival (PFS)** *Two key secondary endpoin

  17. Slide 17: Pre-Specified Mortality Analyses: ASCEND Only

    Pre-Specified Mortality Analyses: ASCEND Only Patients, n (%) HR (95% CI) P-value ‡ All-cause mortality 0.55 (0.26–1.15) 0.1045 Treatment-emergent IPF-related mortality* 0.44 (0.11–1.72) 0.2258 * Deaths adjudicated by mortality assessment committee as directly related to IPF † Occurring during treat

  18. Slide 18: Pre-Specified Mortality Analyses: ASCEND and CAPACITY Pooled

    Pre-Specified Mortality Analyses: ASCEND and CAPACITY (52-week data) Pooled Patients, n (%) HR (95% CI) P-value ‡ All-cause mortality 0.52 (0.31–0.87) 0.0107 Treatment emergent IPF-related mortality * 0.32 (0.14–0.76) 0.0061 * Deaths adjudicated by mortality assessment committee (ASCEND) or investig

  19. Slide 19: Overall Safety Results

    Overall Safety Results Pirfenidone was generally safe and well tolerated with only 4% more treatment discontinuations due to AEs than placebo The most common AEs with higher incidence in the pirfenidone group were primarily gastrointestinal (e.g., nausea and dyspepsia) and skin- related (e.g., rash)

  20. Slide 20: Summary of Treatment Emergent Adverse Events

    Summary of Treatment Emergent Adverse Events* Patients (%) Pirfenidone (N=278) Placebo (N=277) Any adverse event 277 (99.6%) 272 (98.2%) Grade 3 58 (20.9%) 61 (22.0%) Grade 4 8 (2.9%) 14 (5.1%) Any serious adverse event (SAE) 55 (19.8%) 69 (24.9%) Hospitalizations due to respiratory, thoracic, and m

  21. Slide 21: Summary of Top-Line ASCEND Results

    Summary of Top-Line ASCEND Results Primary efficacy endpoint of FVC change achieved (p<0.000001) with clinically meaningful effect size Both key secondary endpoints of 6MWD and PFS achieved Effect not demonstrated on dyspnea (UCSD SOBQ) Additional secondary endpoints showed evidence of an effect on

  22. Slide 22: Dan Welch, Chairman, CEO and President

    Dan Welch Chairman, CEO and President

  23. Slide 23: Next Steps

    Next Steps Anticipate NDA resubmission by early Q3 2014 Class 2 NDA resubmission; six-month review If approved, a U.S. launch could occur in Q2 2015.

  24. Slide 24: InterMune

    @ InteVune™ Lender in PF

  25. Slide 25: InterMune: Leader in IPF

    ee INTERMUNE’ Leader in IPF

InterMune — Technical Presentation (February 2014) on 6ix